期刊文献+

人源性脐带间充质干细胞治疗实验性肺动脉高压所致右心衰竭的疗效观察 被引量:1

Effect of umbilical cord mesenchymal stem cells in the treatment of right heart failure caused by experimental pulmonary arterial hypertension
下载PDF
导出
摘要 目的拟通过建立MCT诱导的PAH大鼠模型,观察人脐带间充质干细胞(UC-MSCs)干预对大鼠PAH和右心衰竭的治疗效应。方法实验动物采用完全随机设计方法分为3组(空白对照组、PAH组和UC-MSCs组),在MCT腹腔注射1周后进行干预,UC-MSCs组舌下静脉注射UC-MSCs悬液,空白对照组和PAH组舌下静脉注射等量生理盐水。第4周大鼠行右心超声心动图、右心导管测压、右心肥厚指数以及肺组织病理等检测。采用SPSS 23.0统计软件进行统计分析,多组间均数比较采用单因素方差分析,P<0.05为差异有统计学意义。结果与对照组相比,PAH组大鼠右心室游离壁厚度(RVWT)和右心室内径(RVID)显著增大[(1.56±0.14)mm比(0.71±0.09)mm,(4.59±0.21)mm比(1.92±0.18)mm,P<0.05],肺动脉血流加速时间与射血时间比值(PAT/PET)显著升高[(39.4±2.68)%比(20.49±2.69)%,P<0.05],右心收缩压(RVSP)和右心肥厚指数(RVHI)显著增高[(52.13±3.38)mm Hg比(14.94±0.75)mm Hg,(68.28±7.25)%比(28.63±1.76)%,P<0.05],肺小动脉血管壁厚度(WT)明显增厚[(24.15±2.54)%比(10.15±0.62)%,P<0.05]。与PAH组相比,UC-MSCs组RVWT和RVID显著减小[(1.17±0.05)mm比(1.56±0.14)mm,(2.95±0.4)mm比(4.59±0.21)mm,P<0.05],PAT/PET明显下降[(25.21±1.31)%比(39.4±2.68)%,P<0.05],RVSP和RVHI明显降低[(38.55±1.98)mm Hg比(52.13±3.38)mm Hg,(44.29±3.98)%比(68.28±7.25)%,P<0.05],WT明显变薄[(15.82±1.75)%比(24.15±2.54)%,P<0.05]。结论利用MCT腹腔注射成功制备PAH大鼠模型,经舌下静脉注射UC-MSCs可以显著降低肺动脉压力,改善右心功能,逆转肺血管重构。 Objective To observe the therapeutic effect of umbilical cord mesenchymal stem cells(UCMSCs)on pulmonary arterial hypertension(PAH)and right heart failure in a Monocrotaline(MCT)induced PAH rat model.Methods The experimental animals were divided into 3 groups by completely random design(control group,PAH group and UC-MSCs group).After 1 week of intraperitoneal injection of MCT,the UC-MSCs group was injected with UC-MSCs suspension intravenously,while the control group and PAH group were injected with the same amount of normal saline intravenously.At the 4th week,the rats were examined by right ventricular echocardiography,right ventricular catheterization manometry,right cardiac hypertrophy index and lung pathology.SPSS 23.0 statistical software was used for statistical analysis.One-way analysis of variance was used to compare the mean between groups.P<0.05 indicates that the difference was statistically significant.Results Compared with the control group,right ventricular free wall thickness(RVWT)and right ventricular inner diameter(RVID)in PAH group were significantly increased[(1.56±0.14)mm vs.(0.71±0.09)mm,(4.59±0.21)mm vs.(1.92±0.18)mm,P<0.05].The ratio of pulmonary acceleration time to ejection time(PAT/PET)was significantly increased[(39.4±2.68)%vs.(20.49±2.69)%,P<0.05].Right ventricular systolic pressure(RVSP)and right ventricular hypertrophy index(RVHI)were significantly increased[(52.13±3.38)mm Hg vs.(14.94±0.75)mm Hg,(68.28±7.25)%vs.(28.63±1.76)%,P<0.05].The arterial wall thickness(WT)was significantly thickened[(24.15±2.54)%vs.(10.15±0.62)%,P<0.05].Compared with PAH group,RVWT and RVID in UC-MSCs group were significantly decreased[(1.17±0.05)mm vs.(1.56±0.14)mm,(2.95±0.4)mm vs.(4.59±0.21)mm,P<0.05].PAT/PET were significantly decreased[(25.21±1.31)%vs.(39.4±2.68)%,P<0.05].RVSP and RVHI were significantly decreased[(38.55±1.98)mm Hg vs.(52.13±3.38)mm Hg,(44.29±3.98)%vs.(68.28±7.25)%,P<0.05].WT was significantly thinner[(15.82±1.75)%vs.(24.15±2.54)%,P<0.05].Conclusion UC-MSCs coul
作者 张玉海 李力兵 王亮 吴远斌 毛磊 李钦 王嵘 ZHANG Yu-hai;LI Li-bing;WANG Liang;WU Yuan-bin;MAO Lei;LI Qin;WANG Rong(Department of Thoracic Surgery,Baotou Clinical Medical College,Inner Mongolia Medical University,Baotou 014040y China;Department of Cardiovascular Surgery,Chinese PLA General Hospital,Beijing 100853,China)
出处 《中国心血管病研究》 CAS 2021年第8期757-763,共7页 Chinese Journal of Cardiovascular Research
关键词 肺动脉高压 右心衰竭 野百合碱 脐带间充质干细胞 Pulmonary arterial hypertension Right heart failure Monocrotaline Umbilical cord mesenchymal stem cells
  • 相关文献

参考文献1

二级参考文献31

  • 1Kiyoko Takemiya,Hisashi Kai,Hideo Yasukawa,Nobuhiro Tahara,Seiya Kato,Tsutomu Imaizumi.Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats[J]. Basic Research in Cardiology . 2010 (3) 被引量:1
  • 2Kawabata M,Miyazono K.Signal transduction of the TGF-beta superfamily by Smad proteins. Journal of Biochemistry . 1999 被引量:1
  • 3Massague J.TGF-β signal transduction. Annual Review of Biochemistry . 1998 被引量:1
  • 4Ramos MF,Lamé MW,Segall HJet al.Smad signaling in the rat model of monocrotaline pulmonary hypertension. Toxicologic Pathology . 2008 被引量:1
  • 5Long L,Crosby A,Yang X,et al.Altered bone morphogenetic protein and transforming growth factor- beta signaling in rat models of pulmonary hypertension:potential for activin receptor -like kinase-5 inhibition in prevention and progression of disease. Circulation . 2009 被引量:1
  • 6B Bartelds,RL Loon,S Mohaupt,H Wijnberg,M Dickinson,B Boersma,J Takens,M Albada,RM Berger.Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension. Chest . 2012 被引量:1
  • 7S. Um ar,Y. P. de Visser,P. Steendijk, et al.Allogenic stem cell therapy improves rightventricular function by improving lung pathology in rats with pulmonary hypertension. AmericanJournal of Physiology . 2009 被引量:1
  • 8Liang OD,Mitsialis SA,Chang MS, et al.Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells . 2011 被引量:1
  • 9Kanki-Horimoto S,Horimoto H,Mieno S, et al.Implantation of mesenchymalstem cells overexpressing endothelial nitric oxide synthase improves right ventricularimpairments caused by pulmonary hypertension. Circulation . 2006 被引量:1
  • 10S. R. Baber,W. Deng,R. G. Master, et al.IntratrAcheal mesenchymal stem cell administrationattenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Amer-ican Journal of Physiology . 2007 被引量:1

共引文献4

同被引文献15

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部